公开(公告)号：US12006320B2

公开(公告)日：2024-06-11

申请号：US17356986

申请日：2021-06-24

申请人： Incyte Corporation

发明人： Stacey Shepard ,  Yanran Ai ,  Andrew P. Combs ,  Nikoo Falahatpisheh ,  Lixin Shao ,  Artem Shvartsbart

IPC分类号： A61K31/4985 ,  A61K31/53 ,  A61P9/00 ,  A61P25/00 ,  A61P35/00 ,  A61P37/00 ,  C07D407/04 ,  C07D487/04 ,  C07D519/00

CPC分类号： C07D487/04 ,  C07D519/00

摘要： This application relates to compounds of Formula (I):




or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

公开(公告)号：US20230043959A1

公开(公告)日：2023-02-09

申请号：US17674237

申请日：2022-02-17

申请人： Incyte Corporation ,  Incyte Holdings Corporation

发明人： Taisheng Huang ,  Chu-Biao Xue ,  Hui-Yin Li ,  Qun Li ,  Anlai Wang ,  Lingquan Kong ,  Hai Fen Ye ,  Wenqing Yao ,  James D. Rodgers ,  Stacey Shepard ,  Haisheng Wang ,  Lixin Shao

IPC分类号： A61K31/4545 ,  C07D487/04 ,  A61P1/00 ,  A61P11/00 ,  A61P35/00 ,  A61P11/06 ,  A61P27/02 ,  A61P17/04 ,  A61P37/06 ,  C07D401/14 ,  C07D405/14 ,  A61K9/00 ,  A61K31/519

摘要： The present invention provides piperidin-4-y1 azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

公开(公告)号：US20230009843A1

公开(公告)日：2023-01-12

申请号：US17356984

申请日：2021-06-24

申请人： Incyte Corporation

发明人： Artem Shvartsbart ,  Stacey Shepard ,  Andrew P. Combs ,  Lixin Shao ,  Nikoo Falahatpisheh ,  Ge Zou ,  Andrew W. Buesking ,  Richard B. Sparks ,  Eddy W. Yue ,  Ravi Kumar Jalluri

IPC分类号： C07D487/04 ,  A61P35/00 ,  A61K31/519 ,  A61P17/06 ,  A61P35/02 ,  A61P37/06 ,  A61P35/04 ,  A61P19/02 ,  C07D519/00

摘要： This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

公开(公告)号：US10472368B2

公开(公告)日：2019-11-12

申请号：US16045358

申请日：2018-07-25

申请人： Incyte Corporation

发明人： Artem Shvartsbart ,  Stacey Shepard ,  Andrew P. Combs ,  Lixin Shao ,  Nikoo Falahatpisheh ,  Ge Zou ,  Andrew W. Buesking ,  Richard B. Sparks ,  Eddy W. Yue ,  Ravi Kumar Jalluri

IPC分类号： C07D487/04 ,  C07D519/00 ,  A61K31/519 ,  A61P35/02 ,  A61P35/04 ,  A61P35/00 ,  A61P19/02 ,  A61P17/06 ,  A61P37/06

摘要： This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

公开(公告)号：US20190276435A1

公开(公告)日：2019-09-12

申请号：US16295705

申请日：2019-03-07

申请人： Incyte Corporation

发明人： Stacey Shepard ,  Andrew P. Combs ,  Nikoo Falahatpisheh ,  Lixin Shao

IPC分类号： C07D403/04 ,  C07D403/14 ,  C07D403/08 ,  C07D413/04 ,  C07D417/04 ,  C07D405/12 ,  C07D241/28 ,  C07D241/20 ,  C07B59/00 ,  A61P35/00 ,  A61P9/00 ,  A61P25/28 ,  A61P37/02

摘要： This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

公开(公告)号：US20180002334A1

公开(公告)日：2018-01-04

申请号：US15688313

申请日：2017-08-28

申请人： Incyte Corporation

发明人： James D. Rodgers ,  Stacey Shepard ,  Haisheng Wang ,  Lixin Shao

IPC分类号： C07D471/14 ,  A61K31/437

CPC分类号： C07D471/14 ,  A61K31/437

摘要： The present invention relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.

公开(公告)号：US09193733B2

公开(公告)日：2015-11-24

申请号：US13896802

申请日：2013-05-17

申请人： Incyte Corporation ,  Incyte Holdings Corporation

发明人： James D. Rodgers ,  Stacey Shepard ,  Wenyu Zhu ,  Lixin Shao ,  Joseph Glenn

IPC分类号： A01N43/90 ,  A61K31/519 ,  C07D487/00 ,  C07D487/04 ,  C07D471/04 ,  C07D491/107

CPC分类号： C07D487/04 ,  C07D471/04 ,  C07D491/107

摘要： The present invention provides piperidinylcyclobutyl substituted pyrrolopyrimidines and pyrrolopyridines of Formula I, as defined herein, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

摘要翻译： 本发明提供如本文所定义的式I的哌啶基环丁基取代的吡咯并嘧啶和吡咯并吡啶以及它们的组合物和使用方法，其调节Janus激酶（JAK）的活性，并且可用于治疗与 JAK包括例如炎症性疾病，自身免疫性疾病，癌症和其它疾病。

公开(公告)号：US20150087632A1

公开(公告)日：2015-03-26

申请号：US14556775

申请日：2014-12-01

申请人： Incyte Corporation

发明人： James D. Rodgers ,  Stacey Shepard ,  Wenyu Zhu ,  Lixin Shao ,  Joseph Glenn

IPC分类号： C07D487/04 ,  C07D471/04

CPC分类号： C07D487/04 ,  C07D471/04

摘要： The present invention provides cyclobutyl substituted pyrrolopyrimidines and pyrrolopyridines of Formula I: wherein X, Y, Z, L, A, R5, n and m are defined above, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

摘要翻译： 本发明提供式I的环丁基取代的吡咯并嘧啶和吡咯并吡啶：其中X，Y，Z，L，A，R 5，n和m如上定义，以及它们的组成和使用方法，其调节Janus激酶的活性 （JAK），并且可用于治疗与JAK的活性相关的疾病，包括例如炎症性疾病，自身免疫性疾病，癌症和其他疾病。

公开(公告)号：US11952367B2

公开(公告)日：2024-04-09

申请号：US17705079

申请日：2022-03-25

申请人： Incyte Corporation

发明人： Richard B. Sparks ,  Stacey Shepard ,  Andrew P. Combs ,  Andrew W. Buesking ,  Lixin Shao ,  Haisheng Wang ,  Nikoo Falahatpisheh

IPC分类号： C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D487/08 ,  C07D487/10 ,  C07D491/107

CPC分类号： C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D487/08 ,  C07D487/10 ,  C07D491/107

摘要： The present disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that modulate the activity of phosphoinositide 3-kinases-gamma (PI3Kγ) and are useful in the treatment of diseases related to the activity of PI3Kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

公开(公告)号：US11926630B2

公开(公告)日：2024-03-12

申请号：US17537674

申请日：2021-11-30

申请人： Incyte Corporation

发明人： Brent Douty ,  Andrew W. Buesking ,  David M. Burns ,  Andrew P. Combs ,  Nikoo Falahatpisheh ,  Ravi Kumar Jalluri ,  Daniel Levy ,  Padmaja Polam ,  Lixin Shao ,  Stacey Shepard ,  Artem Shvartsbart ,  Richard B. Sparks ,  Eddy W. Yue

IPC分类号： C07D487/04 ,  A61P35/00 ,  A61P25/28

CPC分类号： C07D487/04 ,  A61P25/28 ,  A61P35/00 ,  C07B2200/07 ,  C07B2200/13

摘要： This application relates to compounds of Formula (I):




or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.